Kainomyx — Antimalarial Drug (2021)
Verified$4M
Funder
Recipient
Kainomyx
Date
Sep 2021
Data source
Source
Notes
[Other Scientific Research Areas] Open Philanthropy recommended an investment of $4,000,000 in Kainomyx to develop and produce new drugs to treat malaria and other parasitic diseases, such as cryptosporidiosis and toxoplasmosis. If effective, the new drugs would act by inhibiting cytoskeletal proteins in malarial and other parasites. Our science team believes that there is a need for new antimalarial drugs due to increasing resistance to existing treatments. This follows our May 2020 investment and falls within our work on scientific research, specifically within our interest in advancing human health and wellbeing.
Other Grants by Coefficient Giving
2625| Grant | Recipient | Amount | Date |
|---|---|---|---|
| Janaagraha — Air Quality Grants Assessment | $195K | Dec 2024 | |
| Futurewise — Housing Advocacy in Washington | $450K | Apr 2023 | |
| Exscientia — Agonists for Interferon Lambda | $2.3M | Sep 2023 | |
| Kurzgesagt — Short-form Video Content | $3M | Mar 2022 | |
| Kurzgesagt — Video Production (2023) | $1.7M | May 2023 | |
| Kurzgesagt — Video Creation and Translation | $2.6M | Dec 2021 | |
| Lightcone Infrastructure – General Support | Lighthaven (Event Venue) | $4.5M | Sep 2022 |
| Lightcone Infrastructure — General Support (2023) | Lighthaven (Event Venue) | $3M | Oct 2023 |
| Conjecture — Cybersecurity Bootcamp | Conjecture | $223K | Jun 2025 |
| Conjecture — AI Safety Technical Program | Conjecture | $224K | May 2023 |
Showing 10 of 2625 grants